Seliforant

DB15220InvestigationalSmall molecule

Seliforant is under investigation in clinical trial NCT01260753 (Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge).

Mechanism: Pharmacologically active on Histamine H4 receptor
Curator reviewed
Formula / weight: C₁₂H₂₁N₅ · 235.335 g/mol (avg)
Code names: UR-63325

Resolves to

Compound

UNIIB61N8R7TDHCAS1164115-89-2

Structure

InChIKeyQRBVUFXEMHNIDB-UHFFFAOYSA-NSMILESCNC1CN(C1)C1=CC(N)=NC(CC(C)C)=N1

Targets

Q9H3N8HRH4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Seliforant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account